Daniel Barocas, MD
Urology · Nashville, TNNPI 1225259831
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Progenics Pharmaceuticals, Inc. at 58.3% of the total. Reporting peaked in 2023 at $7,676 and has fallen 94.6% since, to $413 in 2025.
Across 32 payments — averaging $551.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Progenics Pharmaceuticals, Inc.$10K
- Pfizer$2K
- Astellas Pharma US Inc$2K
- Photocure Inc$1K
- Ambu Inc.$800
- Johnson & Johnson$405
- plus $1K from 6 others
What the payments were for
- Consulting fees$9,82256%
- Speaking & faculty fees$5,07529%
- Food & beverage$2,73916%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Progenics Pharmaceuticals, Inc. | 6 | $10,275 |
| Pfizer | 2 | $2,092 |
| Astellas Pharma US Inc | 1 | $1,932 |
| Photocure Inc | 8 | $1,129 |
| Ambu Inc. | 1 | $800 |
| Johnson & Johnson | 5 | $405 |
| Urogen Pharma, Inc. | 2 | $305 |
| Bayer | 2 | $263 |
| KARL Storz Endoscopy-america | 2 | $210 |
| Janssen Scientific Affairs, LLC | 1 | $146 |
| Intuitive Surgical | 1 | $41 |
| Ferring Pharmaceuticals Inc. | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,636 in reported general payments places this provider in the 80th percentile of 276 urology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 45 | $129,332 |
| Finasteride | 45 | $519 |
| Silodosin | 11 | $483 |
| Tamsulosin Hcl | 51 | $472 |
Paid to pharmacies, not to this prescriber.
Other urology in Nashville
- L KnollNashville$2.1M
- Gautam JayramNashville$1M
- Roger DmochowskiNashville$763K
- Ashley TapscottNashville$425K
- Raoul ConcepcionNashville$339K
- Melissa KaufmanNashville$312K
- Sam ChangNashville$198K
- Benjamin DehnerNashville$165K
- Smita deNashville$100K
- Nicole MillerNashville$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.